Greg Babcock, Ph.D.
Greg Babcock joined Visterra in 2013 and has over 15 years of experience researching and developing monoclonal antibodies for a variety of disease indications. Previously, Greg served as the Deputy Director of MassBiologics, building and leading the research efforts at the organization. While at MassBiologics, he discovered and developed four human monoclonal antibodies, primarily for infectious disease targets, that were studied in human clinical trials. Two of these antibodies, bezlotoxumab (Zinplava, for the treatment of recurrent C. difficile infection) and RAB1 (Rabishield, post-exposure prophylaxis for rabies virus) have been approved for human use globally and in India, respectively. Greg has authored approximately 50 peer-reviewed publications and numerous patents in the field of monoclonal antibodies.

Greg received his BS in Microbiology from the University of Massachusetts, Amherst and his Ph.D. in Immunology from Tufts University, Sackler School of Graduate Biomedical Sciences where he developed the model for Epstein Barr virus long-term latency in humans. Following his graduate work, he did his post-doctoral training at Harvard Medical School/Dana Farber Cancer Institute studying the biology of HIV co-receptor usage and viral entry.
Jean L Bender
Jean Bender joined Visterra in 2018 and has over 25 years of bioprocess engineering experience within the biopharmaceutical industry. Prior to Visterra, Jean served as Senior Director, BioProcess Engineering at Medimmune LLC where she was responsible for process development engineering, scale-up and transfer of drug substance processes to internal and external manufacturing sites. Previously she held roles of increasing responsibility within Genentech Inc., most recently as Principal Engineer in Purification Development in which she was responsible for tech transfer and licensure of monoclonal antibody processes within the Genentech/Roche manufacturing network. She has authored more than 15 publications and presentations within her field and holds a patent for preparing highly concentrated antibodies by ultrafiltration.

Jean received her MS in Chemical Engineering from the University of California, Berkeley and her BS in Chemical Engineering from Lehigh University.
Todd Curtis
Todd Curtis joined Visterra in 2015 and has more than 10 years of finance and operations leadership experience within the biotechnology and software sectors and an additional 15 years of senior finance experience across several other industries and organizations, from startups to public companies. Prior to joining Visterra, Todd served as Interim CFO and Controller at Mascoma Corporation and in senior financial positions at Cognition Financial Corporation and Fishery Products International, Inc. Prior to joining industry, he was an accountant in the Boston office of Ernst & Young, LLP.

Todd received an MSA/MBA from Northeastern University’s Graduate School of Professional Accounting, and a BS in Mathematics and Economics from Hamilton College in Clinton, New York. Todd is also a licensed CPA.
Chris Kiefer
Chris Kiefer joined Visterra in 2017 and has more than 15 years of life science industry and private practice legal experience. Prior to Visterra, Chris served as Associate General Counsel at Momenta Pharmaceuticals and in senior legal positions at Ironwood Pharmaceuticals and Genzyme Corporation. Prior to joining industry, he was a corporate, securities and transactional attorney with the Boston law firm of Palmer & Dodge. Chris has extensive legal experience in the areas of corporate governance, securities law, collaborations and licensing transactions, corporate finance and healthcare law and compliance.

Chris received a JD from Boston University, a MA in Political Science from the University of Illinois at Urbana-Champaign and a BA in Philosophy and Political Science from Westminster College in Fulton, Missouri.
Greg Miller
Greg Miller joined Visterra in 2013 bringing more than a decade of pharmaceutical business development, strategy and general management experience. Prior to Visterra, Greg served as Vice President of Business and Corporate Development at Concert Pharmaceuticals where he secured numerous collaborations related to the company's drug development platform, including transactions with Avanir Pharmaceuticals, Jazz Pharmaceuticals, and Celgene Corporation, which culminated in the company’s IPO. Previously, he was Senior Director of Business Development and Corporate Strategy at AMAG Pharmaceuticals where he led the efforts in establishing a multi-regional partnership with Takeda Pharmaceuticals. Greg began his pharmaceutical career at Genzyme Corporation in 2002, where he held various roles in business development, licensing, marketing, and reimbursement. Greg has established partnerships in the biopharmaceutical industry generating more than $135 million in upfront payments and over $2.5 billion in potential future milestones.

Greg received a BA in Psychology from Brandeis University, and both an MBA and an MPH from Boston University.
David Oldach, MD, FIDSA
David Oldach joined Visterra in 2017 and has more than 25 years of experience in the biotechnology industry and academia. Prior to joining Visterra, David served as CMO at Cempra Pharmaceuticals developing antibiotics for multiple indications. Previously he served as Director of Clinical Research at Gilead, working in HCV and HBV antiviral drug development. Prior to joining industry, David was on the faculty of the University of Maryland School of Medicine, serving as Infectious Diseases Division Chief at the Baltimore Veterans Affairs Medical Center, with a joint appointment as investigator in the Institute of Human Virology. David has authored more than 75 manuscripts, invited editorials, and book chapters across a range of disease topics.

David received his M.D., magna cum laude, from the University of Maryland School of Medicine, trained in Internal Medicine at Massachusetts General Hospital and in Infectious Diseases at Johns Hopkins Hospital.
Brian Pereira, MD
Brian Pereira joined Visterra in 2013 and is a veteran biopharmaceutical and healthcare leader with experience in financing and growing companies. Prior to joining Visterra, Brian served as the President and CEO of AMAG Pharmaceuticals where he raised $0.5 billion in financing at increasing valuations, and built the clinical development, manufacturing, supply-chain, and commercial infrastructure for the company’s lead program, Feraheme. Previously he held senior roles at Tufts Medical Center including President and CEO of the Tufts Medical Center Physician Organization, interim COO, Vice-Chairman for Strategic Development of the Department of Medicine, and staff physician. Brian is Chairman of the Board of Directors of NephroPlus Ltd and is on the Board of Directors of Africa Healthcare Network and the Biotechnology Innovation Organization (BIO). He serves on the President’s Council of Tufts University and was previously the Chairman of the Board of the Harvard-MIT Biomedical Enterprise Program and President and Board member of the National Kidney Foundation. Brian is an Adjunct Professor of Medicine at Tufts University School of Medicine and has authored over 200 published scientific articles.

Brian received his medical degree (MBBS) from St. John's Medical College, MD (Medicine) and DM (Nephrology) from the Post Graduate Institute, and MBA from Kellogg Graduate School of Management at Northwestern University.
Zachary Schriver
Zachary Shriver joined Visterra in 2009 as Vice President of Research and has over 17 years of experience in the biotechnology industry. Prior to Visterra, Zachary was one of the founding scientists at Momenta Pharmaceuticals and served as its Senior Director of Research Analytics. While at Momenta, Zachary led the development of state-of-the-art analytical techniques to design a number of complex mixture (polysaccharide, polypeptide, and biologics-based) products, supporting multiple INDs and NDAs. Zachary is an inventor on over 50 issued patents and has authored over 80 publications, including original research on the structure and biology of complex polysaccharides, antibody engineering, and describing protein-glycan interactions.

Zachary received his BA in Chemistry, summa cum laude, from Amherst College and his PhD in Applied Biosciences from MIT, where his research focused on sequencing complex polysaccharides through the integration of analytical and bioinformatics-based techniques.
Visterra, Inc.  |  275 2nd Avenue  |  Waltham, MA 02451  |  617-498-1070  |  © 2018 Visterra, Inc. All Rights Reserved.